Non-Hodgkin Lymphoma

Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

Lawrence D. Kaplan, MD, discusses frontline treatment options in follicular lymphoma.

Parameswaran Venugopal, MD, discusses current and emerging treatment strategies in non-Hodgkin lymphoma.

Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either Burkitt lymphoma/leukemia or high-grade B-cell lymphoma.

REGN1979 demonstrated antitumor activity with an acceptable safety profile in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

The combination of polatuzumab-vedotin (Polivy), obinutuzumab (Gazyva), and lenalidomide (Revlimid) induced a high rate of durable responses in patients with relapsed/refractory follicular lymphoma.

With a variety of available agents in follicular lymphoma, determining which treatments to choose and how best to sequence them can be challenging.

Kieron Dunleavy, MD, discusses emerging treatment options and when to use the watch-and-wait approach in follicular lymphoma.

Jason Westin, MD, discusses patient responses with relapsed/refractory diffuse large B-cell lymphoma in the JULIET trial who were treated with tisagenlecleucel.

Mitchell R. Smith, MD, PhD, professor of medicine, George Washington University, associate center director for clinical investigations, Division of Hematology and Oncology, GW Cancer Center, discusses emerging therapeutic approaches in indolent lymphoma.